Amarin Corp Plcuk (AMRN) Cash from Operations (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Cash from Operations of 6604000.0 for Q2 2026, down 60.23% year-over-year from 16606000.0 in Q2 2025, and up 3.38% quarter-over-quarter from 6388000.0 in Q1 2026.
Amarin Corp Plcuk (AMRN) Cash from Operations (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Cash from Operations for 17 consecutive years, with 6604000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations fell 60.23% year-over-year to 6604000.0; the TTM figure through Jun 2026 stood at 15573000.0 (up 235.15% YoY), while the FY2025 annual figure was 6728000.0, up 121.69% from the prior year.
- Cash from Operations improved to 6604000.0 in Q2 2026 per AMRN's latest filing, from 6388000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 16606000.0 in Q2 2025 and bottomed at 98847000.0 in Q1 2022.
- Historically, Cash from Operations has averaged 10250666.67 across 5 years, with a median of 2554500.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Operations sank 1963.57% — and 2025, when it soared 704.07%.
- Amarin Corp Plc\Uk's Cash from Operations stood at 1552000.0 in 2022, then slumped by 141.56% to 645000.0 in 2023, then tumbled by 1963.57% to 13310000.0 in 2024, then surged by 214.79% to 15278000.0 in 2025, then slumped by 56.77% to 6604000.0 in 2026.
- Business Quant data shows AMRN's Cash from Operations at 6604000.0 in Q2 2026, 6388000.0 in Q1 2026, and 15278000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 6.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.60 Mn |
| Jun 30, 2026 | 6.60 Mn |
| Mar 31, 2026 | 6.39 Mn |
| Mar 31, 2026 | 6.39 Mn |
| Dec 31, 2025 | 15.28 Mn |
| Dec 31, 2025 | 15.28 Mn |
| Sep 30, 2025 | -12.70 Mn |
| Sep 30, 2025 | -12.70 Mn |
| Jun 30, 2025 | 16.61 Mn |
| Jun 30, 2025 | 16.61 Mn |
| Mar 31, 2025 | -12.46 Mn |
| Mar 31, 2025 | -12.46 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Mar 31, 2024 | -12.60 Mn |
| Mar 31, 2024 | -12.60 Mn |